Does MOMELOTINIB Cause Malignant neoplasm progression? 10 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Malignant neoplasm progression have been filed in association with MOMELOTINIB (Ojjaara). This represents 1.1% of all adverse event reports for MOMELOTINIB.
10
Reports of Malignant neoplasm progression with MOMELOTINIB
1.1%
of all MOMELOTINIB reports
0
Deaths
1
Hospitalizations
How Dangerous Is Malignant neoplasm progression From MOMELOTINIB?
Of the 10 reports, 1 (10.0%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MOMELOTINIB. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does MOMELOTINIB Cause?
Thrombocytopenia (89)
Death (77)
Drug ineffective (75)
Anaemia (59)
Diarrhoea (51)
Myelofibrosis (51)
Condition aggravated (49)
Dizziness (41)
Pneumonia (41)
Fatigue (39)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which MOMELOTINIB Alternatives Have Lower Malignant neoplasm progression Risk?
MOMELOTINIB vs MOMETASONE
MOMELOTINIB vs MOMETASONE FUROATE
MOMELOTINIB vs MOMETASONE FUROATE\OLOPATADINE
MOMELOTINIB vs MONOMETHYL
MOMELOTINIB vs MONTELUKAST